Abstract:Metabolic engineering of P. pastoris achieves NMN production by semi‐biosynthesis and de novo biosynthesis, which represents the highest yield of de novo synthesis of NMN from basic carbon sources yet reported. β‐Nicotinamide mononucleotide (NMN) is a precursor of NAD+ in mammals. Research on NAD+ has demonstrated its crucial role against aging and disease. Here two technical paths were established for the efficient synthesis of NMN in the yeast Pichia pastoris, enabling the production of NMN from the low‐cost nicotinamide (NAM) or basic carbon sources. The yeast host was systematically modified to adapt to the biosynthesis and accumulation of NMN. To improve the semi‐biosynthesis of NMN from NAM, nicotinamide phosphoribosyltransferases were expressed intracellular to evaluate their catalytic activities. The accumulation of extracellular NMN was further increased by the co‐expression of an NMN transporter. Fine‐tuning of gene expression level produced 72.1 mg/L NMN from NAM in flasks. To achieve de novo biosynthesis NMN, a heterologous biosynthetic pathway was reassembled in yeast cells. Fine‐tuning of pathway nodes by the modification of gene expression level and enhancement of precursor generation allowed efficient NMN synthesis from glucose (36.9 mg/L) or ethanol (57.8 mg/L) in flask. Lastly, cultivations in a bioreactor in fed‐batch mode achieved an NMN titre of 1004.6 mg/L at 165 h from 2 g NAM and 868 g glucose and 980.4 mg/L at 91 h from 160 g glucose and 557 g ethanol respectively. This study provides a foundation for future optimization of NMN biosynthesis by engineered yeast cell factories.

Harnessing lactic acid bacteria for nicotinamide mononucleotide biosynthesis: a review of strategies and future directions

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer’s Disease

Biosynthesis of Nicotinamide Mononucleotide: Current Metabolic Engineering Strategies, Challenges, and Prospects

Biological production of nicotinamide mononucleotide: a review

Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide

An Overview of Engineering Microbial Production of Nicotinamide Mononucleotide.

Nicotinamide Mononucleotide Improves the Alzheimer's Disease by Regulating Intestinal Microbiota

Technology and functional insights into the nicotinamide mononucleotide for human health

High-Level Production of Nicotinamide Mononucleotide by Engineered Escherichia Coli.

Enhancing the biosynthesis of nicotinamide mononucleotide in Lactococcus lactis by heterologous expression of FtnadE

Metabolic Engineering of Bacillus licheniformis for the Bioproduction of Nicotinamide Riboside from Nicotinamide and Glucose

Nicotinamide mononucleotide production by fructophilic lactic acid bacteria

De novo biosynthesis and nicotinamide biotransformation of nicotinamide mononucleotide by engineered yeast cells

Recent Advances in the Chemical Synthesis of β-Nicotinamide Mononucleotide

Enhanced Production of Β-Nicotinamide Mononucleotide with Exogenous Nicotinamide Addition in Saccharomyces Boulardii-Ys01.

Systematic Engineering of Escherichia coli for Efficient Production of Nicotinamide Mononucleotide From Nicotinamide

Enhancing nicotinamide mononucleotide production from glucose in Escherichia coli by genetic engineering

A novel pH-stat fed-batch strategy to boost the production of nicotinamide mononucleotide by high cell density fermentation

Biosynthesis of β-nicotinamide mononucleotide from glucose via a new pathway in Bacillus subtilis

Metabolic engineering of Escherichia coli for optimized biosynthesis of nicotinamide mononucleotide, a noncanonical redox cofactor

Design and tailoring of an artificial DNA scaffolding system for efficient production of nicotinamide mononucleotide